Question explored with the scientific record
Is ivermectin suitable for cancer?
The short version: ivermectin has plausible anticancer mechanisms in the lab, but no clinical trial has shown it improves survival or shrinks tumors in people.
Every piece of evidence for ivermectin as a cancer treatment comes from cell cultures and animal models, not from patients. In glioma cells, ivermectin triggers autophagy and apoptosis at concentrations around 2–15 µM [2, 4]. In breast cancer cells, it induces an inflammatory cell death that releases danger signals, potentially turning a "cold" tumor into one the immune system can attack [5, 8]. A 2023 review lists multiple pathways ivermectin hits: it inhibits AKT/mTOR and Wnt signaling, blocks multidrug resistance transporters, and reduces cancer stem cell markers [1]. These are real mechanisms, and they are the same kind of preclinical signal that hundreds of other drugs have shown before failing in human trials.
The gap is enormous. The only human data in the evidence is a 2023 survey from Ecuador where 19% of cancer patients reported self-medicating with ivermectin, with no efficacy measurement at all [3]. A 2025 case report used ivermectin to treat a parasitic infection in a lung cancer patient, not the cancer itself [6]. That is the entire clinical record in this evidence set. No randomized trial, no survival comparison, no tumor response data in humans.
| Evidence type | What it shows | What it does not show |
|---|---|---|
| Cell-culture studies (glioma, breast, colon, ovarian) | IC50 values 1–16 µM; multiple anticancer mechanisms [1, 2, 4, 5, 7] | Whether those concentrations are reachable in human tumors without toxicity |
| Animal models (rat glioma, mouse breast cancer) | Tumor volume reduction with nanoformulations [9, 10] | Whether any formulation works in humans at safe doses |
| Human survey (Ecuador, n=48) | 19% of cancer patients use ivermectin [3] | No efficacy or safety data |
| Human case report (n=1) | Ivermectin cleared a parasite in a cancer patient [6] | No effect on cancer itself |
The burden of proof has not been met. A drug that kills cancer cells in a dish is a candidate for further study, not a treatment. The evidence here is all preclinical, and the human data is absent. My call: ivermectin is not suitable for cancer based on current evidence. Confidence: high that the clinical evidence does not exist.
Sources examined 12
-
Old wine in new bottles: Drug repurposing in oncology
A comprehensive narrative review detailing how eight non-oncologic drugs (artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide) have demonstrated anticancer activity across in vitro, in vivo, and limited clinical contexts, outlining the…
DOI: 10.1016/j.ejphar.2019.172784 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489 -
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador
This study investigates the use of ivermectin as an alternative treatment for cancer in rural areas of Loja, Ecuador, revealing that a significant percentage of cancer patients self-medicate with this antiparasitic drug despite a lack of scientific endorsement for its efficacy i…
DOI: 10.3390/nursrep13010030 -
The river blindness drug I vermectin and related macrocyclic lactones inhibit WNT ‐ TCF pathway responses in human cancer
This study identifies Ivermectin and related macrocyclic lactones as effective inhibitors of the WNT-TCF signaling pathway in human cancer cells, suggesting their potential therapeutic use against various cancers.
DOI: 10.15252/emmm.201404084 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
A Case Report of Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
This case report documents HTLV-1-associated disseminated Strongyloides stercoralis infection developing after chemoradiotherapy for lung cancer in a non-endemic area of Japan, successfully treated with daily ivermectin followed by six months of intermittent dosing, highlighting…
DOI: 10.2169/internalmedicine.5829-25 -
Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
This study investigates the synergistic effects of ivermectin and pitavastatin on ovarian cancer cell lines, demonstrating that their combination enhances anti-cancer activity and may reduce the required dosage of pitavastatin.
DOI: 10.3390/diseases11010049 -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
This study demonstrates that ivermectin can convert cold breast tumors into hot tumors by inducing immunogenic cell death and enhancing T cell infiltration, thereby synergizing with immune checkpoint blockade for improved treatment outcomes.
DOI: 10.1038/s41523-021-00229-5 -
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression
This study demonstrates nose-to-brain delivery of ivermectin nanocarriers (polymeric nanocapsules and mesoporous silica particles) to suppress glioma growth in a rat model, with intranasal polymeric nanocapsules significantly reducing tumor size and improving histology at a clin…
DOI: 10.1021/acsbiomaterials.5c00642 -
Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management
The study develops biomimetic platelet-membrane camouflaged ivermectin nanocrystals (PMV/Ivm-NC) using a sonoprecipitation method and platelet membrane coating to achieve targeted tumor homing, immunogenic cancer cell death, and enhanced antitumor/antimetastatic effects against …
DOI: 10.1007/s13346-025-02032-2 -
Single-cell RNA sequencing reveals neutrophil differentiation-related genes for immunotherapy response prediction in colorectal cancer
Single-cell RNA sequencing of colorectal cancer reveals neutrophil differentiation–related genes that predict immunotherapy response and identifies Ivermectin as a potential adjunct therapeutic strategy.
DOI: 10.1186/s12885-025-15355-7 -
Antiproliferative and Trypanocidal Activity of Ivermectin Bioconjugates
This study synthesizes ten ivermectin bioconjugates with diverse bioactive partners (cinchona alkaloids, nucleosides, metronidazole, betulinic acid, artesunate) using carbonate, urethane, or click-type linkers, and evaluates their antiproliferative activity against four human ca…
DOI: 10.1021/acsomega.5c02998